SCHEMBL2284232

SCHEMBL2284232

COCCN(C(N)=O)c1cccc(/C=C/C(=O)c2c(O)cc(C)[nH]c2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.41
LMNA P02545 7/20 0.41
HTT P42858 4/20 0.41
MAPT P10636 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
ABCG2 Q9UNQ0 2/20 0.40
PKM P14618 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
CYP2C19 P33261 1/20 0.38
PAX8 Q06710 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ABCB1 P08183 1/20 0.36
PSMD14 O00487 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275775 0.79 LMNA (0.45) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2281141 0.78 LMNA (0.54) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2281145 0.78 LMNA (0.54) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2281153 0.77 BCHE (0.48) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2281156 0.77 BCHE (0.48) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2281949 0.77 ABCG2 (0.47) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2281943 0.77 ABCG2 (0.47) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2280683 0.77 LMNA (0.43) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2277168 0.77 BCHE (0.49) SMN1; SMN2LMNAHTTMAPTNPSR1
SCHEMBL2277165 0.77 BCHE (0.49) SMN1; SMN2LMNAHTTMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 SMN1; SMN2 3766/4885LMNA 537/4885HTT 4798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.